Product image of Ivabradine Milpharm (Ivabradine) supplied by GNH India

Ivabradine Milpharm

Active Ingredient:
Ivabradine
Origin:
EU

Ivabradine Milpharm (Ivabradine)

Ivabradine, the active ingredient in Ivabradine Milpharm, is a If channel inhibitor presented as an oral dosage form for oral use. It lowers heart rate without affecting myocardial contractility and is indicated for chronic stable angina and heart failure with reduced ejection fraction.\n\nGNH India supplies Ivabradine Milpharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Milpharm Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Ivabradine acts on the cardiac If current to control heart rate in specific cardiovascular conditions.\n\nChronic stable angina: reduces the frequency of angina attacks by lowering heart rate while preserving contractile function.\nHeart failure with reduced ejection fraction: improves symptoms and may decrease hospitalisation by maintaining a lower, steady heart rate.

How It Works

  • Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, which is responsible for spontaneous depolarisation. By blocking this inward sodium/potassium mixed current, the drug slows the pacemaker activity, producing a dose‑dependent reduction in heart rate without altering myocardial contractility or systemic vascular resistance.

Side Effects

  • Ivabradine is generally well tolerated, but several adverse reactions have been reported.\n\nCommon Side Effects:\n- Bradycardia: heart rate falls below the desired range.\n- Visual disturbances (phosphenes): transient luminous phenomena.\n- Headache: mild to moderate intensity.\n- Dizziness or vertigo: especially on standing.\n- Fatigue: reduced energy levels.\n\nSerious or Rare Side Effects:\n- Severe bradycardia leading to syncope.\n- Atrial fibrillation or other supraventricular arrhythmias.\n- Symptomatic hypotension with dizziness or fainting.\n- Vision loss or persistent visual impairment (rare).

Precautions & Warnings

  • Before initiating therapy, clinicians should evaluate cardiovascular status and monitor heart rate regularly.\n\nCardiovascular assessment: confirm baseline heart rate and rhythm.\nAvoid in severe sinus node dysfunction: contraindicated in patients with sick sinus syndrome.\nCaution with concomitant bradycardic agents: monitor when used with beta‑blockers or digoxin.\nHepatic impairment: dose adjustment may be required in moderate to severe liver disease.\nPregnancy and lactation: safety not established; use only if benefits outweigh risks.\nStore at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

  • Ivabradine may interact with several medicines that affect heart rate or its metabolism.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can markedly increase plasma levels.\n- Other bradycardic agents (beta‑blockers, digoxin): may cause excessive heart‑rate reduction.\n- Drugs that prolong AV conduction (verapamil, diltiazem): increase risk of atrioventricular block.\n\nModerate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may require dose adjustment.\n- Antihypertensives (ACE inhibitors, ARBs): monitor blood pressure for additive effects.\n- QT‑prolonging agents: observe for any changes in cardiac repolarisation.

Frequently Asked Questions

Ivabradine Milpharm is prescribed to lower heart rate in patients with chronic stable angina and in those with heart failure with reduced ejection fraction. By reducing the heart rate, it helps relieve angina symptoms and improves functional capacity in heart‑failure patients.

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the pacemaker of the heart. This inhibition slows spontaneous depolarisation, leading to a controlled reduction in heart rate while preserving myocardial contractility and blood pressure.

The dose of Ivabradine Milpharm is individualized by the prescribing clinician based on the patient’s heart‑rate target, renal and hepatic function, and concomitant medications. The prescriber determines the appropriate strength and dosing schedule.

Safety data for ivabradine during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so without affecting myocardial contractility or blood pressure, making it useful when beta‑blockers are contraindicated or insufficient. Beta‑blockers also reduce sympathetic activity, providing broader cardiovascular effects.

Store Ivabradine Milpharm at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Ivabradine Milpharm is taken orally, usually with or without food, as directed by the prescriber. The tablets should be swallowed whole with a glass of water and not crushed or chewed.

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, and rare visual disturbances that may affect vision. Patients should be monitored for these events, especially during dose initiation and when combined with other heart‑rate‑lowering drugs.

Ivabradine is contraindicated in patients with severe sinus node dysfunction, advanced atrioventricular block, resting heart rate below 50 bpm, uncontrolled hypotension, or those taking strong CYP3A4 inhibitors. It should also be avoided in individuals with known hypersensitivity to the drug.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Ivabradine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT